Does Medicare Cover GLP-1 Weight Loss Medication in 2026? What the New Bridge Program Means for You

As of July 1, 2026, Medicare Part D beneficiaries may be eligible to access GLP-1 weight loss medications — including Wegovy and Zepbound — for as little as $50 per month under a new federal demonstration program called the Medicare GLP-1 Bridge. This is a significant shift in how Medicare approaches obesity treatment, and it opens the door for millions of seniors who were previously priced out of these medications.

Here is what you need to know.

What Is the Medicare GLP-1 Bridge Program?

The Medicare GLP-1 Bridge (formally part of the BALANCE — Better Approaches to Lifestyle and Nutrition for Comprehensive Health — Program) is a temporary demonstration program run by the Centers for Medicare and Medicaid Services (CMS). It launched July 1, 2026 and is currently scheduled to run through December 31, 2027.

The program negotiated a fixed $50 per month co-pay for certain GLP-1 medications, available to eligible Medicare Part D plan participants at select pharmacies including Walgreens.

Medications currently included in the Bridge program include:

• Wegovy (semaglutide) — indicated for chronic weight management
• Zepbound (tirzepatide) — indicated for chronic weight management
• Foundayo — a newer GLP-1 formulation added to the program

Important: GLP-1 medications are not controlled substances, which means they can be prescribed via telehealth without the in-person visit requirements that apply to stimulant medications like Adderall.

Who May Qualify for the Medicare GLP-1 Bridge?

Eligibility for the Bridge program is determined by CMS based on several factors. As of publication, CMS has confirmed the following general criteria:

• You must be enrolled in a Medicare Part D plan that participates in the Bridge demonstration
• You must meet clinical criteria for GLP-1 treatment (typically a BMI of 30 or greater, or 27 or greater with a weight-related comorbidity such as hypertension, type 2 diabetes, or sleep apnea)
• A licensed provider must submit a Prior Authorization Request on your behalf to CMS for review

CMS has not published detailed denial and reapplication procedures as of this writing. Coverage determinations may vary, and enrollment decisions are subject to CMS review.

Disclaimer: Coverage eligibility and benefit determinations under the Medicare GLP-1 Bridge program vary by individual circumstances and plan participation. This article is for informational purposes only. Please verify your specific benefits with your Medicare Part D plan and a licensed provider before pursuing treatment.

How the Prior Authorization Process Works

Unlike standard prescription coverage, the Medicare GLP-1 Bridge requires a coordinated prior authorization between your provider and your pharmacy before you can access the $50 co-pay pricing. Here is the general process:

1. Speak with a licensed provider on or after July 1, 2026. Your provider will evaluate whether you meet the clinical criteria for GLP-1 treatment.
2. Your provider submits a Prior Authorization Request to CMS. This form documents your clinical need and is submitted jointly through the provider and pharmacy.
3. CMS reviews the request. Once approved, you can access your GLP-1 medication at the $50/month rate at participating pharmacies.

Telehealth providers — including board-certified physicians and nurse practitioners — can complete this process remotely, meaning you do not need to visit an in-person clinic to initiate a Bridge program application.

What If I Don't Have Medicare Part D, or Am Denied?

The Bridge program is a demonstration, not a universal entitlement. Not everyone with Medicare will qualify, and not all Part D plans may participate. If you are denied or do not have Part D coverage, there are still options:

• Manufacturer savings programs: Novo Nordisk (Wegovy) and Eli Lilly (Zepbound) both offer savings cards for commercially insured patients that may significantly reduce out-of-pocket costs.
• Telehealth GLP-1 programs: Many telehealth providers offer GLP-1 treatment programs at competitive monthly rates, sometimes including the medication and provider visits in a single bundled fee.
• HSA/FSA funds: In most cases, GLP-1 medications prescribed for a medical purpose (obesity, metabolic syndrome) qualify as HSA/FSA-eligible expenses.

Why Telehealth Makes GLP-1 Access Easier

Visiting an in-person bariatric clinic or endocrinologist for GLP-1 treatment often means waiting weeks or months for an appointment. Telehealth platforms with licensed providers can typically schedule an initial evaluation much faster — and because GLP-1 medications are not controlled substances, there are no DEA-imposed in-person visit requirements.

At Klarity Health, our network of 2,000+ licensed providers includes physicians and nurse practitioners who can evaluate whether GLP-1 treatment may be appropriate for you, walk you through your insurance options, and coordinate any necessary prior authorization — all via video visit from home.

See if you may qualify for GLP-1 treatment through Klarity. Verify your benefits and check your coverage options.

Key Dates and Caveats to Know

One important caution raised by healthcare policy experts: the program is a time-limited demonstration. Patients who begin GLP-1 therapy under the Bridge should be aware that access at the $50 co-pay rate is not guaranteed beyond December 2027. Stopping GLP-1 medications abruptly is associated with weight regain, so it is worth discussing a long-term access plan with your provider.

The Bottom Line

The Medicare GLP-1 Bridge program is a meaningful step toward making effective weight loss treatment accessible to Medicare beneficiaries. If you or a loved one is on Medicare Part D and struggling with obesity or a weight-related condition, it is worth speaking with a licensed provider to find out whether you may be eligible.

Disclaimer: Coverage, eligibility, and benefit details described in this article reflect information available as of July 2026 and are subject to change. Always verify your specific plan benefits with CMS, your Part D plan, and a licensed healthcare provider before beginning any treatment program.

Check if you may qualify for GLP-1 treatment via telehealth